Find Academic Supervisors

• Machine Learning in Drug Design and Discovery
• Environmental Analysis
• Natural Product Chemistry
• +3 more

Dr. Kassim Adebambo is a researcher at the Centre for Research in Mechanisms of Disease and Drug Discovery, part of the School of Life and Medical Sciences at the University of Hertfordshire. Previously, he held roles as a Teaching Fellow at the University of Aberdeen and lecturing positions at Nigerian universities, including Tai Solarin University of Education and Olabisi Onabanjo University. He has industry experience with Nitech Solution, focusing on optimizing crystallization processes and omega-3 extraction in fish oil using Continuous Oscillatory Batch Reactor techniques. Dr. Adebambo holds a B.Sc. (Hons) in Chemistry from Ondo State University (now Ekiti State University), an M.Sc. in Organic Chemistry (Natural Products) from the University of Ibadan, a PhD in Medicinal Chemistry from Heriot-Watt University, and an M.Sc. in Advanced Drug Delivery from the University of Strathclyde. His research interests span multiple areas: applying machine learning and data science to drug design and discovery, analyzing environmental contaminants like trace metals and PFAS in food and the environment, isolating and characterizing natural products' secondary metabolites, and developing smart drug delivery systems, particularly liposomal technologies. He has collaborated on studies involving molecular docking to investigate potential treatments for Alzheimer's disease, SARS-CoV-2, malaria, and HIV. Notably, his work includes computational studies on anti-inflammatory drugs against SARS-CoV-2 proteins and in silico investigations into novel Alzheimer's therapies. While no specific scientific awards are mentioned, his contributions to drug discovery and environmental analysis have been published in peer-reviewed journals. Dr. Adebambo's current affiliations and past roles reflect a career dedicated to advancing pharmaceutical research through interdisciplinary approaches, combining computational methods with practical applications in drug delivery and environmental chemistry.

• Medicinal Chemistry
• Biochemistry
• Pharmacology
• +7 more

Francois DURANT is a Professor at the University of Namur, with extensive research activity spanning medicinal chemistry, structural biology, and materials science. His work focuses on enzyme inhibition, drug design, and surface chemistry techniques. Active in HIV-1 nonnucleoside reverse transcriptase inhibitors Specializes in 5-LOX/COX-2 dual inhibitors Contributed to STM-based molecular imaging and ester group identification Research trends include antiviral therapy development (2009), structural insights into inflammation pathways (2006), and surface chemistry innovations (2005). Publications highlight interdisciplinary approaches combining computational modeling with experimental validation. No scientific awards were explicitly mentioned in the provided text. Collaborative projects span lipid crystallization, chocolate rheology, and biological absorption prediction.

• Medicinal Chemistry
• Drug Design
• Antiviral Agents
• +6 more

Valentina Noemi Madia is a Researcher (RTD-A) at Sapienza University of Rome, Department of Chemistry and Technologies of Drugs, where she focuses on the design and synthesis of small molecules active against emerging viruses. She has been with the university since completing her PhD in 2017 and has established herself as a prominent researcher in medicinal chemistry with over 43 peer-reviewed publications, one international patent, and one book chapter. Her educational background includes: PhD in Life Sciences (with mark "Excellent") from Sapienza University of Rome (2017) Master's Degree in Pharmacy (110/110 summa cum laude) from Sapienza University of Rome (2013) Qualification for the practice of the pharmacist profession (2014) Dr. Madia's research centers on the design and development of heterocyclic small molecules with diverse biological activities. Her work spans multiple therapeutic areas including antiviral agents (targeting HIV, coronaviruses, HCV, polio, and influenza), antifungal, antibacterial, antiprotozoal, anticancer, and anti-Alzheimer agents. She employs modern drug design approaches such as computer-aided drug design, parallel synthesis, and green chemistry techniques including microwave-assisted and flow chemistry synthesis. Her publication record shows a strong focus on antiviral drug development, particularly against HIV and SARS-CoV-2, with numerous articles on structure-activity relationships of heterocyclic compounds. She has also made significant contributions to the development of antiprotozoal, anticancer, and antifungal agents, demonstrating the breadth of her expertise in medicinal chemistry. Dr. Madia has received several prestigious awards for her work: Best Poster Presentation Prize from the European Federation of Medicinal Chemistry (2024) Medicinal Chemistry Division Prize from the Italian Chemical Society (2024) Premio Soroptimist 2021 for the best research project Multiple travel grants from the Italian Chemical Society for national and international meetings As an educator, Dr. Madia serves as a teacher for "Fundamentals of Chemical Biology I" and has supervised numerous undergraduate and PhD students since 2017. She has secured research funding as both principal investigator and participant, including projects focused on HIV-1 ribonuclease H inhibitors and SARS-CoV-2 protease inhibitors. Her service to the scientific community includes membership on the Topical Advisory Panel for Pharmaceuticals journal and peer reviewing for multiple scientific publications.

Sam MbulaiteyeView profile

Academic

• Burkitt Lymphoma
• Cancer Epidemiology
• HIV/AIDS and Cancer
• +4 more

Sam Mbulaiteye is a Senior Investigator in the Infections and Immunoepidemiology Branch (IIB) at the National Cancer Institute's Division of Cancer Epidemiology and Genetics (DCEG). Based at the NCI Shady Grove campus, he leads groundbreaking research on the etiology of Burkitt lymphoma (BL), particularly in sub-Saharan Africa where it has the highest incidence. His work bridges epidemiology, immunology, and molecular biology to understand the complex interplay between infectious agents and cancer development. Dr. Mbulaiteye received his physician training at Makerere University, Kampala (1990), advanced training in epidemiology and biostatistics (M.Phil.) from the University of Cambridge, U.K. (1994), and specialist training in internal medicine (M.Med.) from Makerere University (1996). His early research focused on measuring the impact of HIV on cancer in patients at the Uganda Cancer Institute (1994-1997) and investigating population trends of HIV in rural southwest Uganda. He joined the IIB in December 2000 as a research fellow focusing on Kaposi sarcoma and BL, and was awarded NIH scientific tenure and appointed Senior Investigator in 2013. His primary research focus is characterizing the epidemiology of Burkitt lymphoma across different settings. In Western countries, he uses registry-based datasets to investigate age-specific incidence rates for BL, suggesting disease heterogeneity may vary with age. In sub-Saharan Africa, where BL is the most common childhood tumor, he quantifies associations between BL and serological or molecular markers of malaria and Epstein-Barr virus (EBV) infection, and investigates the role of metabolites as potential nutritional or geographical co-factors. Dr. Mbulaiteye implemented the multi-country EMBLEM (Epidemiology of Burkitt Lymphoma in East-African Children and Minors) study across six rural regions in Uganda, Tanzania, and Kenya to collect high-quality data on BL etiology. Dr. Mbulaiteye's recent publications (2023-2025) demonstrate a strong focus on the genetic and molecular underpinnings of Burkitt lymphoma in African populations. His work spans genome-wide association studies, DNA methylation analysis, metabolomics, and investigations into the interplay between malaria, EBV, and BL risk. A significant portion examines how host genetic factors, including HLA variants and sickle cell trait, influence BL susceptibility in endemic regions. His research has established critical links between malaria exposure patterns and BL risk, challenging previous assumptions about the relationship between falciparum malaria and this cancer. Scientist of the Year by the Lymphoma Foundation of America (2022) DCEG Outstanding Mentor Award (2025) Dr. Mbulaiteye serves as Co-Editor-in-Chief of Infectious Agents and Cancer and is on editorial boards for AIDS, International Journal of Cancer, and Frontiers in Cancer Epidemiology and Prevention. He actively mentors researchers through his leadership of the EMBLEM study and collaborations across Africa. He is a member of the African Organization for Research and Training in Cancer (AORTIC), the Darwin College Society, the Cambridge Commonwealth Trust, and the World Federation of Scientists, and is a Founding Member of the Burkitt Lymphoma Network. He has organized scientific sessions about Burkitt lymphoma at the last four biennial AORTIC meetings and was invited by IARC/WHO in 2021 to assist in revising the Burkitt Lymphoma chapter in the WHO Classification of Tumours.

• Bacterial Immunity
• CRISPR-Cas Systems
• Molecular Microbiology
• +3 more

Mario Rodríguez Mestre is a Research Fellow in the Department of Biology specializing in Microbiology at the University of Copenhagen. His research focuses on elucidating molecular mechanisms of bacterial immunity against viral infections and genetic elements. His primary research interests include: CRISPR-Cas systems and their evolutionary adaptations Reverse transcriptase-mediated defense mechanisms Nucleotide-based signaling in bacterial immune responses Bacteriophage resistance pathways Noncoding RNA regulation of bacterial immunity Prokaryotic defense system diversity Dr. Mestre's recent publications (2022-2025) demonstrate an impressive trajectory in understanding bacterial defense systems, with work appearing in premier journals including Science, Nucleic Acids Research, and Molecular Cell. His research particularly advances knowledge of type IV and type VI CRISPR-Cas systems, retrons, and the UG/Abi family of reverse transcriptases, revealing novel mechanisms of bacterial self-defense. His collaborative work has garnered significant attention across academic and public spheres, with multiple publications covered by news outlets and widely shared across social media platforms, indicating the broad relevance and impact of his research contributions to microbial immunity.

Seth ShipmanView profile

Associate Professor

• Neurodevelopmental Diseases
• Neurodegenerative Diseases
• Pharmacogenomics
• +7 more

Seth Shipman is an Associate Professor at the University of California San Francisco (UCSF) within the Department of Bioengineering and Therapeutic Sciences. He holds a joint appointment as an Associate Investigator at the Gladstone Institute of Data Science and Biotechnology, where his research intersects molecular biotechnology with neurodevelopmental and neurodegenerative disease studies. His work emphasizes pharmacogenomics, genomics, and therapeutic bioengineering, leveraging DNA as a programmable biological polymer for data storage and targeted therapeutics. Education: PhD in Biochemistry and Biophysics (2012), University of California San Francisco Dr. Shipman's research focuses on overcoming technical barriers in disease understanding and treatment through molecular engineering. His lab specializes in CRISPR-Cas systems, retron gene editors, and DNA-based cellular recording technologies. Key areas include neurodevelopmental mechanisms, progressive neurodegeneration, and context-specific gene therapies. Scientific awards highlight his contributions: NIH Director’s New Innovator Award (2020), Pew Biomedical Scholar (2020), and recognition in ScienceNews as a top scientist (2019). His work has been featured in journals like Nature , Nature Biotechnology , and Science , with recent publications analyzing retron systems for genome editing and transcriptional recording in E. coli. Notable Awards: NIH Director’s New Innovator Award (2020) Pew Biomedical Scholar (2020) ScienceNews SN 10: Scientists to Watch (2019) DARPA Riser (2018) The Shipman Lab develops innovative tools like CRISPR-Cas encoding for digital movie storage in bacterial genomes (2017) and retron arrays for multi-site genome editing (2024). Their work bridges synthetic biology and clinical applications, particularly for diseases involving cellular change dynamics.

Steven ZimmerlyView profile

Professor

• RNA Biology
• Molecular Genetics
• Evolutionary Biology
• +3 more

Steven Zimmerly is a Professor in the Department of Biological Sciences at the University of Calgary, Faculty of Science. His research focuses on group II introns' catalytic RNA properties, retroelement behavior, and evolutionary implications. He holds a B.A. in Chemistry from Goshen College (1986) and a Ph.D. in Biophysics from Yale University (1992). Research interests include the self-splicing mechanisms of group II introns, their mobility strategies, structural diversity, and evolutionary relationships. Notably, his work revealed how some introns insert after transcriptional terminators to avoid disrupting host genes. Zimmerly has contributed to databases tracking mobile group II introns and elucidated their roles in horizontal gene transfer and parasitic genomic dynamics. He has been recognized with the GREAT Supervisor Award (2018), AHFMR Senior Scholar (2003), and AHFMR Scholar (1998). Courses taught include BCEM 413 (Laboratory Techniques II) and CMMB 451 (Molecular Analysis of Biological Systems). Over 15 key publications span RNA structure-function studies, retroelement evolution, and bacterial genomic analyses. Grants & Funding: Not explicitly listed in the text. Labs/Teams: Research group focuses on RNA biology and molecular evolution; collaborates widely (e.g., with Lambowitz, Doulatov, and others).

Bradley D. GelfandView profile

Assistant Professor

• Age-Related Macular Degeneration
• Immunology
• Molecular Biology
• +12 more

Bradley D. Gelfand, Ph.D., is an Assistant Professor in the Department of Ophthalmology at the University of Virginia School of Medicine. His research integrates biomedical engineering, immunology, and molecular biology to study age-related macular degeneration (AMD) and retinal disease mechanisms. B.S., University of Iowa, 2004 Ph.D., University of Virginia, 2010 Postdoctoral Training, University of Kentucky, Department of Ophthalmology and Visual Sciences, 2012 Dr. Gelfand's research focuses on the molecular and biomechanical underpinnings of ocular diseases, particularly AMD. His work explores hemodynamics in the choroidal vasculature , DICER1 deficiency , Alu RNA toxicity , and inflammasome activation . Utilizing tools from medical imaging , signal processing , fluid mechanics , and computational modeling , his lab investigates how biomechanical and molecular changes in the eye's microenvironment lead to vision loss. His recent publications reveal key insights into the role of hemodynamic forces , inflammatory signaling (via NLRP3 and MyD88), and RNA processing defects in AMD. These studies, published in journals like Cell , Science , and Nature Communications , highlight converging pathways in retinal degeneration involving iron toxicity , reverse transcriptase inhibition , and endothelial cell regulation . Dr. Gelfand leads active research projects funded through grants focusing on the cellular and molecular consequences of blood supply in the eye. His lab employs high-resolution 3D microscopy and computational fluid dynamics to model choroidal anatomy and hemodynamics. He also uses advanced cell culture systems to simulate ocular hemodynamic environments for mechanistic studies. He advises students through his research laboratory and contributes to training the next generation of physician-scientists and biomedical engineers. Though no formal list of students is provided, his lab environment supports graduate and postgraduate research.

• Medicinal Chemistry
• Pharmaceutical Chemistry
• Drug Design
• +4 more

Andrea Tafi is an Associate Professor at the University of Siena, affiliated with the Department of Biotechnology, Chemistry and Pharmacy. His office and laboratory are located in the university's Scientific Campus (Polo Scientifico Universitario), where he conducts research and teaches courses including Quantitative Pharmaceutic Analysis for the Chemistry and Pharmaceutical Technologies program. His research spans medicinal chemistry, drug design, and computational modeling , with specific focus on developing novel therapeutics through structure-activity relationship studies. Key areas include cannabinoid receptor ligands, GPCR-targeted compounds, and enzyme engineering for environmental bioremediation. Recent work integrates machine learning for pharmaceutical applications like antibody-drug conjugate optimization. Publications demonstrate strong emphasis on: Rational drug design of receptor modulators (cannabinoid, prokineticin, GABA receptors) Computational methods including 3D-QSAR and pharmacophore modeling Synthetic chemistry for bioactive scaffolds Interdisciplinary approaches combining biotechnology, toxicology, and AI

Connie WuView profile

Researcher

• cancer biology
• RNA therapeutics
• biomolecular engineering
• +7 more

Connie Wu, Ph.D., is a Research Assistant Professor at the Life Sciences Institute and holds dual appointments as Assistant Professor of Biomedical Engineering (College of Engineering) and Pharmaceutical Sciences (College of Pharmacy) at the University of Michigan. Her lab develops transformative technologies at the intersection of materials engineering, single-molecule detection, and biomedical applications to address challenges in cancer diagnostics and RNA therapeutics. Education: B.S. in Chemical Engineering (Yale University, 2013), Ph.D. in Chemical Engineering (MIT, 2018), Postdoctoral Research Fellow (Harvard Medical School, 2018-2022) Wu's research focuses on Accelerating cancer biomarker signature discovery using ultrasensitive single-molecule assays Engineering multifunctional RNA therapeutics for cancer immunotherapy Designing rational nanomaterials with predictable in vivo behavior Creating high-multiplex diagnostic platforms for blood-based disease detection Her work combines hypothesis-driven and hypothesis-free approaches to overcome bottlenecks in biomarker validation and therapeutic translation. Scientific awards include NIH NIBIB Trailblazer Award (2024) NIH Maximizing Investigators' Research Award (2024) Department of Defense Idea Award (2024) NIH Ruth L. Kirschstein Postdoctoral Fellowship (2020-2022) NSF Graduate Research Fellowship (2014-2017) Wu's laboratory trains students and researchers from diverse backgrounds in biomedical engineering, chemical biology, and molecular diagnostics. Current lab members include research staff, postdoctoral fellows (Evan Alexander, Chia-Wei Yang), graduate students (Ashley Haralson, Chi-Chia Wang, Yinying Yang), and alumni (Andrew Alvarez, Wenxuan Wang, Ryan Schildcrout). The lab actively recruits at all levels and emphasizes interdisciplinary collaboration. The lab's technology development spans Digital single-molecule detection platforms RNA sequence/structural design for immunotherapy Nanopore-based immunoassays Polycationic carrier systems for nucleic acid delivery Multi-cancer biomarker validation Predictive nanomaterial design tools

• Virology
• Cell Biology
• Molecular Biology
• +1 more

Arturo Diaz is an Associate Professor of Biology at La Sierra University , specializing in the study of positive-strand RNA viruses and their interactions with host cells. His research aims to uncover molecular mechanisms for antiviral therapy development. Education Ph.D., Microbiology - University of Wisconsin-Madison, 2009 B.S., Molecular, Cell and Development Biology - University of California, Los Angeles, 2003 Research Focus : Diaz investigates how viruses like brome mosaic virus (BMV) manipulate host factors to form RNA replication compartments. His lab uses Saccharomyces cerevisiae as a model to study membrane remodeling, lipid metabolism, and protein interactions essential for viral replication. Scientific Awards : National Science Foundations Grant (2017-2020) NIH NRSA Postdoctoral Fellowship (2009-2011) Carl Storm Underrepresented Minority Fellowship (2011) NIH Predoctoral Fellowship (2003-2006) Advancement Opportunity Fellowship, UW-Madison (2006-2008) Center for Academic and Research Excellence Scholar (2000-2001) Publication Trends : His work spans virology, molecular biology, and cell biology, focusing on RNA replication compartments, host factor exploitation, and CRISPR-based antiviral strategies. Recent studies highlight lipid metabolism and membrane dynamics in viral replication.

Dimitrios ParaskevisView profile

Professor

• Infectious Disease Epidemiology
• Molecular Epidemiology
• Public Health
• +3 more

Dimitrios Paraskevis is a Professor of Epidemiology and Preventive Medicine at the National and Kapodistrian University of Athens, School of Medicine, Department of Hygiene, Epidemiology and Medical Statistics. He plays a pivotal role in Greece's public health infrastructure as a member of the Ministry of Health’s emergency committee on Infectious Diseases and the National Public Health Organization's Board of Directors. PhD in Molecular Epidemiology of Infectious Diseases Expert on HIV and SARS-CoV-2 epidemiology Active in pandemic response and policy-making His research focuses on infectious disease epidemiology , with emphasis on molecular tracking of HIV-1 and SARS-CoV-2 transmission patterns, vaccine effectiveness, and public health interventions during pandemics. Key subfields include drug resistance dynamics, wastewater surveillance, healthcare-associated infections, and cross-border disease spread. Over the past three years, his work has addressed climate change health impacts , emerging viral mutations , and healthcare policy evaluation . Paraskevis has authored over 280 publications and sits on the editorial boards of seven peer-reviewed journals. His leadership roles in national health organizations highlight his commitment to improving Greece's public health systems through evidence-based strategies.

Scott NelsonView profile

Associate Professor

• DNA Repair
• DNA Replication
• Molecular Biology
• +3 more

Scott Nelson is an Associate Professor at Iowa State University in the Department of Biochemistry, Biophysics and Molecular Biology. His research focuses on DNA repair mechanisms, particularly the Mre11/Rad50 (MR) complex, and DNA replication in Plasmodium falciparum, the malaria parasite. He investigates structural and functional aspects of these systems using enzymology and molecular biophysics. His work aims to understand molecular mechanisms of DNA repair and replication, with applications in antimalarial drug discovery. Education: B.S. in Biotechnology, North Dakota State University (1997) Ph.D. in Biochemistry, Iowa State University (2002) Postdoctoral Fellow in Chemistry, Pennsylvania State University (2003–2008) Research Interests: Dr. Nelson's lab explores the MR complex's role in double-strand break repair and the apicoplast DNA replication machinery in Plasmodium falciparum. Techniques include cryo-EM, proteomics, and enzymatic assays. Recent work emphasizes structural biology of apicoplast DNA polymerase and small molecule inhibitors targeting this enzyme. Publications: Recent studies highlight advancements in understanding Mre11 mutations, apicoplast DNA polymerase structures, and antimalarial drug candidates. Trends include interdisciplinary approaches combining structural biology with drug discovery. Labs/Teams: The Nelson Lab focuses on molecular mechanisms of DNA repair and replication, with collaborations in structural biology and parasitology.

• Pharmacology
• Biochemistry
• Molecular Biology
• +3 more

Nicholas Mullins is a Lecturer in the Department of Pharmaceutical Science and Biotechnology at the Faculty of Science and Health. His research focuses on pharmacology and molecular biology, particularly in ion channels and nucleoside-related mechanisms. His work contributes to UN Sustainable Development Goals related to health and well-being. Research interests include Large Conductance Calcium-Activated Potassium Channels, nucleoside functions, reverse transcriptase, and cellular processes. These areas intersect with drug development and pharmacological applications. No scientific awards were listed in the provided information. Nicholas Mullins has no listed advisees or grants in the available data. No specific laboratories or research teams are detailed in the profile.

Karen ErrichettiView profile

Assistant Professor

• Public Health Informatics
• Healthcare Innovation Implementation
• Health Equity
• +5 more

Karen Errichetti is an Assistant Professor in the Department of Public Health and Community Medicine at Tufts University School of Medicine. She holds a DrPH from Boston University, an MPH from Yale University, and a BA from Wellesley College. Her expertise spans program evaluation, health planning, and public health informatics, with a focus on healthcare innovations and health equity at the U.S.-Mexico border. She has over 15 years of experience in consulting, nonprofit leadership, and public service, including roles as Director of Research and Evaluation at Health Resources in Action and Director of Digital Services at the National Institute for Children's Health Quality. Dr. Errichetti's research emphasizes making public health data accessible to underserved communities and building their capacity for self-driven research. She teaches courses such as Program Planning and Evaluation, Public Health Integration, and Qualitative Methods at Tufts. Her work bridges academic research with practical community engagement, particularly in marginalized border regions. Education: DrPH, Boston University School of Public Health MPH in Epidemiology of Microbial Diseases, Yale University BA in Biological Sciences, Wellesley College Research Interests: Implementation of healthcare innovations at the US-Mexico border Health equity in public health decision-making Data visualization for community accessibility Public health policy evaluation, including anti-bullying policies and pay-for-performance models Teaching and Professional Service: Course instructor for program evaluation, public health policy, and qualitative methods Former elected member of the North Reading School Committee (MA) Senior leadership roles in non-profits focused on children's health and health informatics Labs/Teams: Collaborates with cross-sector partners through the Sí Texas partnership-centered evaluation model, focusing on border health initiatives.